Dapagliflozin attenuates progression from prefrailty to frailty in patients with hypertension and chronic kidney disease.

What was studied

This study followed older adults. They had high blood pressure, chronic kidney disease and early signs of frailty. 135 people aged over 65 were followed for 1 year. The groups were balanced with a statistical method, leaving 105 people. 52 of them took dapagliflozin. The team looked at kidney damage, physical performance and frailty. Walking speed was one measure of physical performance.

What they found

More kidney damage was linked to worse physical performance. Slower walking went with more albumin in the urine. Slower walking also went with a lower eGFR, a kidney test. People taking dapagliflozin had lower odds of becoming frail at 1 year. The odds ratio was 0.130.

What it means for patients

The authors said greater kidney injury was linked to worse physical performance. They said dapagliflozin may play a protective role against loss of function in this group.

Why it is not certain yet

The abstract reports links from statistical models after the groups were balanced. It does not say people were put into groups by chance. Only 105 people were in the final group, followed for 1 year.

Source

Dapagliflozin attenuates progression from prefrailty to frailty in patients with hypertension and chronic kidney disease.

We restate facts from the source record in our own words. The original wording belongs to its publisher.